MED

Value Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM Total revenue 115.73 M105.56 M89.41 M75.1 M76.04 M 346.1 M Gross profit 84.25 M76.64 M62.16 M52.14 M51.76 M 242.7 M Operating expenses 85.89 M77.72 M66.85 M60.31 M55.11 M 259.99 M Selling/general/admin expenses 85.51 M77.71 M66.24 M59.94 M55.05 M 258.94 M Research & development ————— — Operating income -1.26 M-1.07 M-4.08 M-7.8 M-3.29 M -16.25 M Non-Operating Income, Total 1.79 M3.94 M1.42 M1.42 M1.35 M 8.14 M Interest expense, net of interest capitalized ————— — Non-Operating Income, excl. Interest Expenses 1.79 M1.37 M1.43 M1.42 M1.38 M 5.59 M Unusual income/expense 487 K2.57 M-2 0001 000-25 K 2.55 M Pretax income 526 K2.88 M-2.66 M-6.38 M-1.94 M -8.11 M Equity in earnings ————— — Taxes 1.3 M395 K-396 K11.74 M181 K 11.92 M Non-controlling/minority interest ————— — After tax other income/expense ————— — Net income before discontinued operations -772 K2.48 M-2.26 M-18.12 M-2.12 M -20.02 M Discontinued operations ————— — Net income -772 K2.48 M-2.26 M-18.12 M-2.12 M -20.02 M Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders -772 K2.48 M-2.26 M-18.12 M-2.12 M -20.02 M Basic earnings per share (Basic EPS) -0.070.23-0.21-1.65-0.19 -1.82 Diluted earnings per share (Diluted EPS) -0.070.22-0.21-1.64-0.19 -1.82 Average basic shares outstanding 10.95 M10.99 M10.99 M10.98 M11.01 M — Diluted shares outstanding 10.95 M11.06 M10.99 M10.98 M11.01 M — EBITDA 2.4 M2.97 M-1.24 M-4.71 M125 K -2.85 M EBIT -1.65 M-1.07 M-4.69 M-8.18 M-3.36 M -17.3 M Cost of revenue 31.48 M28.91 M27.25 M22.96 M24.29 M 103.41 M Other cost of goods sold ————— — Depreciation & amortization (cash flow) 3.28 M4.04 M3.45 M3.46 M3.48 M 14.45 M